Evidence map›Paper›PMID 33184754›Full record

Trial reportInternational journal of clinical oncology2021

Randomized phase II trial of carboplatin + nab-paclitaxel versus cisplatin + gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan lung cancer study group 1302.

Yosuke Kawashima, Toshiyuki Harada, Yuka Fujita, Taku Nakagawa, Kana Watanabe, Naoto Morikawa, Kei Takamura, Kenya Kanazawa, Tomoya Kuda, Kazuhiro Usui and 3 more

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International journal of clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 1 country.

Yosuke KawashimaDepartment of Pulmonary Medicine, Sendai Kousei Hospital, 4-15 Hirosemachi, Aoba-ku, Sendai, 980-0873, Japan.
Toshiyuki HaradaDepartment of Respiratory Medicine, JCHO Hokkaido Hospital, 1-8-3-18, Nakanoshima, Toyohira-ku, Sapporo, 062-8618, Japan.
Yuka FujitaDepartment of Respiratory Medicine, National Hospital Organization Asahikawa Medical Center, 7-4048 Hanasakimachi, Asahikawa, 070-8644, Japan.
Taku NakagawaDepartment of Thoracic Surgery, Omagari Kosei Medical Center, 8-65 Omagaritorimachi, Daisen, 014-0027, Japan.
Kana WatanabeDepartment of Respiratory Medicine, Miyagi Cancer Center, 47-1 Nodayama, Shiote, Medeshima, Natori, 981-1293, Japan.
Naoto MorikawaDivision of Pulmonary Medicine, Allergy, and Rheumatology, Iwate Medical University School of Medicine, 2-1-1 Odori, Yahabamachi, Iwate, 028-3695, Japan.
Kei TakamuraDepartment of Pulmonary Medicine, Obihiro Kosei Hospital, 10-1 West 14 South, Obihiro, 080-0024, Japan.
Kenya KanazawaDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Tomoya KudaDepartment of Respiratory Medicine, Naha City Hospital, 2-31-1 Furujima, Naha, 902-8511, Japan.
Kazuhiro UsuiDivision of Respirology, NTT Medical Center Tokyo, 5-9-22 Higashi-Gotanda, Shinagawa-ku, Tokyo, 141-8625, Japan.
Akimasa SekineDepartment of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomiokahigashi, Kanazawa-ku, Yokohama, 236-0051, Japan.
Akira InoueDepartment of Palliative Medicine, Tohoku University School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.
Shunichi SugawaraDepartment of Pulmonary Medicine, Sendai Kousei Hospital, 4-15 Hirosemachi, Aoba-ku, Sendai, 980-0873, Japan. swara357@sendai-kousei-hospital.jp.ORCID http://orcid.org/0000-0002-3427-4558
Sendai Kousei Hospital · JPAsahikawa Medical College Hospital · JPFukushima Medical University · JPHokkaido hospital · JPIwate Medical University · JPKanagawa Cardiovascular and Respiratory Center · JPMiyagi Prefectural Hospital Organization · JPNaha City Hospital · JPNTT Medical Center · JPObihiro Kosei General Hospital · JPTohoku University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA subset analysis of the CA031 trial showed significant improvement in the overall response rate after administration of carboplatin plus weekly albumin-bound paclitaxel compared to carboplatin plus paclitaxel for squamous cell carcinoma of the lung (SQ). We conducted this phase II study to compare carboplatin plus weekly albumin-bound paclitaxel (CnP) to cisplatin plus gemcitabine (CG), a standard regimen for SQ.

methodsChemotherapy-naïve patients with SQ were randomly assigned to receive cisplatin (80 mg/m

resultsBetween June 2013 and October 2018, 71 patients were enrolled and assigned to either the CG arm (n = 35) or the CnP arm (n = 36) of the study. The overall response rate was 43% [95% confidence interval (CI) 27.3-58.5] in the CG arm and 47% (95% CI 31.7-62.7) in the CnP arm. Although drug combination efficacies did not differ, there were differences in toxicity: hematologic toxicities (leukopenia, neutropenia, and thrombocytopenia) were found mostly in the CG arm, whereas anemia and sensory neuropathy were more common in the CnP arm.

conclusionsCnP had similar response as CG despite being a carboplatin-based regimen and toxicities differed between arms. Regarding ORR, CnP was comparable to CG for SQ.

Indexed as

Carcinoma, Squamous CellLung NeoplasmsAlbuminsAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCisplatinDeoxycytidineGemcitabineHumansJapanPaclitaxelTreatment Outcome130-nm albumin-bound paclitaxelAlbuminsCarboplatinCisplatinDeoxycytidineGemcitabinePaclitaxelAlbumin-bound paclitaxelCarboplatinChemotherapyCisplatinGemcitabine

Identifiers

PMID33184754
OpenAlexW3104220902

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.